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ABSTRACT:  
A rapid, simple and highly sensitive spectrofluorimetric method is developed for the determination of Tamsulosin 
hydrochloride (Tams.HCl) in pharmaceutical formulations . The proposed method is based on investigation of the 
fluorescence spectral behavior of Tams.HCl in a sodium dodecyl sulphate (SDS) micellar system. In aqueous solution of 
Tris buffer of pH 7±0.2, SDS causes marked enhancement in the fluorescence intensity of Tams.HCl (about +110%). The 
fluorescence intensity is measured at 328 nm after excitation at 280 nm and the fluorescence-concentration plots are 
rectilinear over the range 0.1-1.2 µg ml
-1
, with lower detection limit of 0.027 µg ml
-1
 and quantification limit of 0.09 µg ml
-1
. 
The method is successfully applied to the analysis  of the studied drug in its commercial capsules, and the results are in 
good agreement with those obtained with the official method. The application of the proposed method is extended to 
stability studies of Tamsulosin hydrochloride after exposure to different forced degradation conditions, such as acidic, 
alkaline and oxidative conditions, according to ICH guidelines. 
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INTRODUCTION: 
Tamsulosin 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2- ethoxybenzene-sulfonamide [1] (Fig. 1). Tamsulosin is 
an alpha1- adrenoceptor blocker; it is reported to be more selective for the alpha 1A-adrenoceptor subtype. It is used in 
benign prostatic hyperplasia to relief symptoms of urinary obstruction. Tamsulosin is given by mouth as the hydrochloride 
salt in a modified-release formulation, in a dose of 400 μg once daily [2]. Several analytical procedures describing the 
determination of Tamsulosin have been published; these methods include non-aqueous titration [3], voltammetry [4] and 
spectrophotometry [5]. Several chromatographic methods were described for determination of Tamsulosin, such as high-
performance liquid chromatography (HPLC) with UV detection [3, 6–9] , fluorescence detection [10] , mass spectrometric 
detection [11–15] , and capillary electrophoresis [16]. 
The key characteristic of fluorescence spectrometry is its high sensitivity. Fluorometry may achieve limits of detection 
several orders of magnitude lower than those of most other techniques. Because of the low detection limits, fluorescence 
is widely used for quantification of trace constituents of biological and environmental samples. Most complex samples 
contain one or more components that can quench the fluorescence of the analyte. Thus, it often is necessary to subject 
complex samples to be analyzed by fluorometry to extensive prior cleanup to remove potential quenchers. Alternatively, 
one may try to provide a uniform microenvironment for the analyte and thus a reproducible fluorescence yield from sample 
to sample by adding a micelle forming surfactant to each sample [17]. This is based on the fact that fluorescent molecules 
in solution may be partially or fully hidden from quenchers by incorporating them into organized media such as surfactant 
micelles or cyclodextrin cavities  [18]. The environment seen by a micelle-solubilized solute differs from that encountered in 
aqueous solution in having a higher local viscosity which decreases collision -induced non-radiative decay or possible 
quenching reactions, resulting in increased fluorescence quantum yield with a subsequent increase in analytical  sensitivity 
[19]. Recently, micelle-enhanced fluorescence using sodium dodecyl sulfate (SDS) has been utilized for the 
spectrofluorometric determination of Ezetimibe [20], loratadine and desloratadine [21], galantamine [22], verapamil 
hydrochloride [23], gatifloxacin [24], garenoxacin in human urine and serum [25], naproxen [26], Levofloxacin [27], 
ellipticine [28], carbendazim [29] and fenproporex [30]. Surveying the literature revealed that there is no reported 
spectrofluorometric method for the determination of Tams.HCl using organized media. Tams. HCl is considered as a minor 
pharmaceutical active ingredient which needs highly sensitive methods to be determined in its dosage forms and 
biological fluids. The objective of the present work is to study the effect of SDS micellar medium on enhancing the native 
luminescence characters of Tams.HCl in order to develop a new simple and sensitive micro analytical methodology for 
determination of the studied drug in its dosage forms. 
EXPERIMENTAL: 
Apparatus 
All the fluorescence spectra were recorded using a JASCO FP-6200 Spectrofluorometer, equipped with 150 W Xenon 
lamp, grating excitation and emission monochromators, and a recorder. Slit widths for both monochromators were set at 
10 nm; they were set at 5 nm for fluorescence quantum yield measurements. A 1 cm quartz cell was used. Spectra were 
evaluated using Spectra Manager FP-6200 Control Driver software, Version 1.54.03 [Build 1], JASCO Corporation.  
Materials and reagents 
a) Pure materials: 
- Tams.HCl, was purchased from SIGMA pharmaceutical industries  (Osmopharm , Swittazerland), its percent purity was 
100.68% as received. 
b) Pharmaceutical preparations: 
 -Tamsulin capsules Manufactured by (Marcyrl Pharmaceutical industries, Elobour City , Egypt), were purchased from 
commercial sources in the local market. Each capsule is labeled to contain 0.4 mg of Tamsulosin HCl.  Batch 
Number1020774 
 -Tamic capsules Manufactured by (Sigma Pharmaceutical industries, Egypt), were purchased from commercial sources in 
the local market. Each capsule is labeled to contain 0.4 mg of Tamsulosin HCl. Batch Number 81774. 
c) Reagents: 
All chemicals used were of analytical reagent grade and were used without further purification.  
 SDS (Rediel –De- Haen , Germany), 1.0 % (W/V) aqueous solution was prepared by dissolving 10 g SDS in distilled 
water, and then it was diluted to1 L with the same solvent. It is stable for 7 days when left in the refrigerator. 
 Β-cyclodextrin was obtained from Merck (Germany), 0.05 % (W/V) aqueous solution was prepared by dissolving 0.5 g 
Β-cyclodextrin in distilled water, and then it was diluted to100 ml with the same solvent. 
 Tris-Chloride buffer [Tris (hydroxyl methyl) amino methane] was obtained from (Fluka Bio Chemika), 0.1 M aqueous 
solution pH 7±0.2 was prepared according to the B.P. 
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 Mcllvaine buffer[31] , pH  ( 2.2-7) was prepared by mixing appropriate volumes of 0.1M citric acid and  0.2 M disodium 
hydrogen orthophosphate, both citric acid and  disodium hydrogen orthophosphate were obtained from El -Nasr 
Pharmaceutical Chemical Co. (ADWIC; Egypt).  
 Methanol HPLC grade 99.9 % (Sigma , Germany )  
 Hydrochloric acid HPLC grade 37 % ( Rediel –De- Haen , Germany) , 2.0 M aqueous solution was prepared. 
 Sodium chloride (Winlab , Leicestershire, U.K.) 
 Sodium hydroxide pellets (Winlab , Leicestershire, U.K.) 2.0 M aqueous solution was prepared. 
Standard solutions 
Tams. HCl Stock solutions: 
Stock solution 1 (250.0µg ml
-1
) was prepared by dissolving 25.0 mg of Tams. HCl in 100.0 ml of methanol.  
Stock solution 2 (20.0µg ml
-1
) was prepared by diluting 8.0 ml of Stock solution 1 to 100.0 ml with distilled water.  
Tams. HCl working solution: 
A working solution (4 µg ml
-1
) was prepared by diluting 20.0 ml of Stock solution 2 to 100.0 ml with distilled water.   
General procedures 
a) Procedure for calibration graph. 
Aliquots from Tams.HCl working solution equivalent to (1.0-12.0 µg) Tams.HCl were transferred into a series of 10-ml 
volumetric flasks. Then 2.0 ml 0.1 M Tris-Chloride buffer solution, pH 7±0.2, were added to each flask, followed by 2.0 ml 
1.0% w/v SDS solution. The volume was completed with distilled water; the contents of the flasks were mixed well. A blank 
experiment was performed simultaneously and the relative fluorescence intensity was measured at 328 nm after excitation 
at 280 nm. The corrected fluorescence intensities were plotted against the final drug concentrations (μg ml
-1
) to obtain the 
calibration graph. Alternatively, the corresponding regression equation was derived.  
b) Procedure for capsules. 
The contents of not fewer than ten capsules were weighed and mixed well. An amount of the capsule pellets equivalent to 
1 mg Tams.HCl was accurately weighed, transferred to 25-ml volumetric flask and dissolved in methanol. The flask was 
sonicated for 30 minutes then, completed to volume with the same solvent. The produced solution (40 μg ml
-1
) was used 
to prepare aqueous working solution (4 μg ml
-1
). Aliquots from working solution covering the concentration range cited in 
table (1) were transferred into a series of 10-ml volumetric flasks, the ‘Procedure for calibration graph’ (above) was then 
performed. The capsule content was determined either from a previously plotted calibration graph or using corresponding 
regression equation. 
c) Procedure for biological fluids. 
Aliquots of human plasma equivalent to 1.0 ml were transferred into centri fugation tubes and spiked with 1.0 ml of 
Tams.HCl. Then, 2.0 ml acetonitril were added to each tube. The mixture was centrifuged at 6000 rpm for 20 minutes. 1 .0 
ml of the supernatant was carefully transferred to a measuring flask and the ‘Procedure for calibration graph’ was then 
applied. A blank experiment was carried out simultaneously. The drug content in plasma was determined using 
corresponding regression equation. 
d) Procedures for stability indicating assay 
 Alkaline and acidic degradation. 
 Aliquots of Tams.HCl Stock solution 1 (equivalent to 250.0 μg of the drug) were transferred into a series of small conical 
flasks; aliquots of 2 M NaOH or 2 M HCl equivalent to 5.0 ml were added. The flasks were heated in a boiling water bath 
for different time intervals (5–60 min). At the specified time intervals , the contents of each flask were cooled and 
neutralized to pH 7.0 with 2 M HCl or 2 M NaOH, respectively. The solutions were then transferred into 25-ml volumetric 
flasks and completed to volume with water. One ml of the resulting solutions was then transferred into 10-ml volumetric 
flasks and the procedure ‘Procedure for calibration graph’ was performed. 
 Oxidative degradation. 
 Aliquots of Tams.HCl Stock solution 1 (equivalent to 250.0 μg of the drug) were transferred into a series of 25 -ml 
volumetric flasks; different volumes of 10% H2O2 were added and the volume was completed with water. One ml of these 
solutions was transferred into 10-ml volumetric flasks and the procedure ‘Procedure for calibration graph’ was performed. 
 Photo-degradation.  
Aliquots of Tams.HCl Stock solution 1 (containing 250.0 μg of the drug) were transferred into 25 -mL volumetric flasks and 
completed to volume with distilled water. The volumetric flasks were exposed to UV light at a wavelength of 254 nm and at 
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a distance of 15 cm, placed in a wooden cabinet, for 5 hours . one ml of the solutions was then transferred into 10-ml 
volumetric flasks and the procedure ‘Procedure for calibration graph’ was performed. 
RESULTS AND DISCUSSION 
Tams.HCl was found to exhibit a weak emission band at 328nm in aqueous Tris -Chloride buffer solution of pH 7 after 
excitation at 280 nm. This work aimed to enhance this emission band, in order to develop a new methodolo gy for the 
analysis of Tams.HCl in its pharmaceutical preparations. The use of different types of surfactants to enhance the 
fluorescence of many drugs has found wide applications in the field of analysis. When a surfactant at a concentration 
above its critical micellar concentration is added to a given fluorophore solution, it increases the molar absorbtivity and/or 
the fluorescence quantum yield of the fluorophore in many cases [32]. This fact has been used to improve the 
performance of spectrofluorimetric methods of various analytes. The fluorescence properties of Tams.HCl were studied in 
different types of organized media (SDS, β- cyclodextrin and Tween 80). Tween 80 caused severe decrease in the RFI of 
the studied drug while the addition of SDS caused an enhancement (about 110%) of its fluorescence intensity compared 
with aqueous solution (Fig. 2). On the other hand β- cyclodextrin showed no marked effect on the fluorescence intensity of 
Tams. HCl (Fig. 3), therefore SDS was used as a fluorescence enhancer in order to develop a new spectrofluorimetric 
method for the determination of Tams. HCl in its dosage form. 
Optimization of the reaction conditions  
a) Effect of pH and type of buffer 
The influence of pH on the micelle enhanced fluorescence of Tams. HCl was studied using different types of buffers 
covering wide pH range, such as Mcllvaine buffer over the pH range 3–7 and 0.1 M Tris-Chloride buffer over the pH range 
7–10. It was found that maximum RFI was achieved over the pH range 4.0–8.0; increasing the pH value above pH 8.0 
caused gradual decreases in the RFI (Fig. 4). Therefore, pH 7 was chosen as the optimum pH value for measurement of 
RFI of the studied drug in SDS medium. Comparison between the RFI of the studied drug in SDS medium of pH 7 was 
carried out using Mcllvaine and Tris-Chloride buffer. No significant difference between the RFI of the drug in the two buffer 
media, so Tris-Chloride buffer was used to adjust the optimum pH for the reaction. 
The pKa value of Tams. HCl is reported to be 8.4 (secondary amine) [1]. This may explain the reason for the maximum 
RFI observed over the pH range 4.0–8.0 at which the studied drug is mostly present in the protonated form which interact 
more strongly with the anionic micelles of SDS than the neutral form. It is also reported that the fluorescence intensity for 
protonated species is always higher than that for neutral species [33].  
b) Effect of the volume of SDS 
 The influence of SDS on the RFI of Tams. HCl was studied using increasing volumes of 1.0% w/v SDS. It was found that 
increasing volumes of SDS solution resulted in a consequent increase in RFI up to 1.0 ml, after which no further increase 
in RFI was observed (Fig. 5). Therefore, 2ml 1.0% w/v SDS solution was chosen as the optimum volume to achieve 
maximum enhancement in RFI of Tams. HCl. 
c) Effect of Molar concentration of Tris buffer 
The effect of Molar concentration of Tris buffer (pH = 7) on the RFI of Tams. HCl in the presence of SDS was studied. 
Different Molar concentrations ranging from 0.025 M up to 0.2 M were used (Fig. 6). No significant difference in the RFI of 
the studied drug was observed upon changing the Molar concentration of buffer, so 0.1 M Tris buffer was used to adjust 
pH of the reaction. 
d) Effect of time  
The effect of time on the RFI of the studied drug was studied over time intervals ranging from five minutes up to two hours. 
It was found that enhancement of the fluorescence intensity was immediately developed and remained stable for two 
hours as shown in  (Fig.7). 
e) Effect of diluting solvent  
The effect of different diluting solvents on the RFI of Tams. HCl in the presence of SDS was investigated using water, 
methanol, n-propanol and acetonitrile. It was found that water was the best solvent for dilution, as it gave the highest RFI 
and the lowest blank reading, also it is cheap, safe and available solvent. Other solvents showed no marked change in the 
RFI of Tams. HCl  (Fig. 8). 
Validation of the proposed method 
 The proposed method was tested for linearity, LOQ, LOD,  accuracy, precision and robustness. 
a) Linearity 
After optimizing the conditions, evaluation of linearity of the assay method was performed by analysing seven 
concentrations for the studied drug (standard calibration plots). The calibration graph of Tams. HCl was constructed by 
plotting the enhanced RFI of the studied drug in SDS medium against final concentration in µg ml
-1
(Fig.9). The 
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fluorescence – concentration plot was linear over the concentration range 0.10 -1.20 μg ml
-1
. Analysis of the data gave the 
following regression equation: 
                          RFI = 829.55 C- 2.150                     (r = 0.9998)      
Where RFI is the relative fluorescence intensity, C is the concentration of the studied drug in (µg ml
-1
) and (r) is the 
correlation coefficient. 
The limit of quantitation (LOQ) was determined by establishing the lowest concentration that can be measured according 
to ICH Q2 (R1) recommendations [34], below which the calibration graph is non-linear. The limit of detection (LOD) was 
determined by evaluating the lowest concentration of the analyte that can be readily detected.  
The values of LOQ and LOD were calculated according to the following equation 
                      LOQ = 10 σ / S                                   LOD = 3.3 σ / S  
Where σ = the residual standard deviation of the regression line   
 And    S = slope of the calibration curve 
The results of LOQ and LOD are summarized in Table (1). The proposed method was e valuated by calculating accuracy 
as percent relative error and precision as percent relative standard deviation, the results are abridged in Table (1). 
Calibration data of Tams. HCl in pure form by the proposed method are presented in Table (1). 
b) Accuracy and Precision 
The results of the proposed method were compared with those obtained using the official method [3]. Statistical analysis 
[35] of the results using Student’s t-test and Variance ratio F-test revealed no significant difference between the two 
methods regarding accuracy and precision, respectively Table (2). 
c) Repeatability 
The repeatability (intra day precision) was evaluated through replicate analysis of the studied drug in pure form and in 
Tamsulin capsule using three different concentrations (0.40, 0.60 and 0.80 µg ml
-1
) and each concentration was measured 
three successive times. The results are summarized in Table (3).  
d) Intermediate Precision 
The Intermediate Precision (inter-day precision) was evaluated through replicate analysis of the studied drug in pure form 
and in Tamsulin capsule on three successive days. The results are abridged in Table (3). The precision of the proposed 
method was fairly high, as indicated by the low values of SD and %RSD, respectively. Also the inter -day and intra-day 
accuracy was proved by the low values of %Er. 
e) Robustness of the method 
The robustness of the proposed method was demonstrated by the constancy of the RFI with minor changes in the 
experimental conditions, such as the pH (7 ± 0.5) and the change in the volume of SDS (2.0 ± 0.5mL). These minor 
changes that may take place during the experimental operation did not affect the RFI.  
Pharmaceutical application 
The proposed method was applied to the determination of Tams. HCl in its commercial dosage forms (Tamsulin capsule, 
Tamic capsule). Tams.HCl is official in the USP and so are its capsules. The USP states that Tams. HCl capsules contain 
not less than 90.0 % and not more than 110.0 % of the labeled amount. The results obtained by the proposed method 
were within the USP stated limit and they were compared with those obtained using the reference method [3] Table (4, 5). 
Statistical analysis of the results obtained using Student’s t-test and Variance ratio F-test revealed no significant difference 
between the performance of two methods regarding accuracy and precision, respectively. 
Biological application 
The proposed method was applied to the determination of Tams.HCl in spiked human plasma. The intra-day precision was 
evaluated through replicate analysis of plasma samples spiked with different concentrations of the studied drug (0.4 and 
0.8 µg ml
-1
). The mean percentage recovery based on the average of five separate determinations of each concentration 
was 99.51± 5.1 .The results are abridged in Table (6). 
Results of stability indicating assay 
Tams.HCl was found to be susceptible to acid degradation after boiling with 2M HCl for 1 hour 18% of the drug was 
degraded. The studied drug was found to be less susceptible to alkaline degradation as only 7% of the drug was degraded 
after boiling with 2M NaOH for 1 hour.  
Oxidative degradation of Tams.HCl with hydrogen peroxide was also studied. It was found that treating the drug with 30% 
H2O2 at room temperature, according to the procedure described above, resulted in immedia te degradation of Tams.HCl. 
The amount of the degraded drug was dependent on the volume of H2O2 added; 84% degradation was observed upon the 
addition of 7.0 ml 30% H2O2 to the drug (Fig. 9).  
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The effect of 10% H2O2 on Tams. HCl was also studied, as shown in Fig. (10), addition of 6.0 ml 10% H2O2 caused 41% 
degradation of the studied drug. The results of stability studies were calculated from fluorescence measurement of 
Tams.HCl in both aqueous and micellar media and they were so close in both conditions.  
The effect of UV light on the stability of Tams.HCl was studied by exposing the aqueous drug solutions to the UV light. No 
considerable degradation was observed upon exposure of the drug to UV light up to 3 hours. 
Mechanism of the micellar enhancement effect of SDS on Tams. HCl fluorescence: 
In order to establish whether the sensitization process of Tams.HCl fluorescence was only due to an increase in quantum 
yield, or whether it was affected by an increase in absorption at the excitation wavelength, the molar absorbtivity of 
Tams.HCl in the presence of SDS was determined at 280nm (λex). Table (7) shows that the ε micellar: ε water ratio was 
approximately 1.0, which indicates that the increase in sensitivity is not affected by an increase in the absorption of the 
studied drug at its λex, but it is due to an increase in the quantum yield of Tams.HCl by protection of the lowest excited 
singlet state in the micellar microenvironment from non-radiative processes. The quantum yield of Tams.HCl was found to 
be 0.029 in aqueous medium and 0.051 in the presence of SDS as shown in Table (8). The quantum yield was calculated 
according to the following equation [36]: 
Фu = [ФsFu/Fs] × [As/Au] 
where Фu and Фs referred to the fluorescence quantum yields of the drug and quinine sulphate (Q.S.), respectively; Fu 
and Fs represented the integral fluorescence intensity of the drug and quinine, respectively; Au and As referred to the 
absorbance of the drug and quinine at the excitation wavelength, respectively.  
CONCLUSION 
The micellar enhanced spectrofluorimetric method proposed for the determination of Tams . HCl, has the advantages of 
simplicity, speed, accuracy, low detection limit and the use of inexpensive equipment. It can be considered as an attractive 
alternative to numerous other more complicated methods. The proposed method could be successfully applied for the 
determination of the studied drug in pure form and in pharmaceutical preparations; the results are in good agreement with 
the official methods.  Moreover, it has been adapted for stability studies of the studied drug as a rapid and simple 
alternative to the reported stability-indicating HPLC methods.  
 
 
C20H28N2O5S                 M.Wt = 408.5  
 
C20H28N2O5S . HCl         M.Wt = 445 
Fig. (1): Tamsulosin Hydrochloride  
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Fig. (2): Emission spectra of Tams. HCl (1.0 μg ml
-1
) in presence of 
(A) : aqueous Tris buffer of pH 7. 
(B) : 1% SDS medium of  pH 7. 
 
 
Fig. (3): Emission spectra of Tams. HCl (1.0 μg ml
-1
) in presence of 
(A) : aqueous Tris buffer of pH 7.  
(C) : 0.5% β –Cyclodextrine of pH 7. 
A 
 
C 
 
A 
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Fig. (4): Effect of pH on the fluorescence intensity of Tams. HCl (0.8 μg ml
-1
) in presence of : ♦  Aqueous , ■ 0.5% β 
–Cyclodextrine and ▲1% SDS media.  
 
 
Fig. (5):Effect of volume of 1% SDS solution on the relative fluorescence intensity  of Tams. HCl 
(0.8 μg ml
-1
). 
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Fig. (6): Effect of Molar concentration of Tris buffer ( pH = 7) on the relative fluorescence intensity of Tams. HCl 
(0.8 μg ml
-1
). 
 
 
Fig. (7): Effect of time on the relative fluorescence intensity of Tams. HCl (0.8 μg ml
-1
). 
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Fig. (8): Effect of diluting solvent on the relative fluorescence intensity of Tams. HCl (0.4 μg ml
-1
). 
 
 
Fig. (9): Calibration graph of Tams. HCl in pure form using SDS system 
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Fig. (10): Plot of relative fluorescence intensity of Tams. HCl (1.0 μg ml
-1
) versus volume of 30% H2O2 in presence 
of : ■  Aqueous  and  ♦1% SDS media. 
 
 
Fig.(11 ):Plot of relative fluorescence intensity of Tams. HCl (1.0 μg ml
-1
) versus volume of 10% H2O2 in presence 
of : ■  Aqueous  and ♦ 1% SDS media. 
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Table (1) : Calibration data and Performance data of the proposed method for determination of  Tams.HCl in pure 
form. 
Parameter 
 
Concentration 
μg ml 
-1
 
RFI at 328 nm 
 0.1 80 
0.2 154 
0.4 335 
0.6 502 
0.8 665 
1.0 831 
1.2 984 
Concentration range (μg ml
-1
) 0.10 -1.20 μg ml
-1
 
Regression equation RFI = 829.55 C- 2.150 
Correlation coefficient (r) 0.9998 
Standard deviation of the residuals  (Sy/x) 7.557 
% Recovery  99.42 
± S D 2.58 
%RSD 2.60 
% Er 0.58 
(LOQ) 0.09 μg ml
-1
 
(LOD) 0.03  μg ml
-1
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Table (2) : Statistical analysis of the results of Tams.HCl in pure form by the proposed method, compared with 
Reference method [3]. 
 
Parameter 
 
 
proposed method  
 
Official method  
USP 
[3]
 
  
μg ml
-1
taken 
 
μg ml
-1 
found 
 
% Recovery  
 
 
% Recovery  
 
0.10 0.099 99.00  
99.0 
 
100.7 
 
101.2 
 
101.8 
0.20 0.188 94.00 
0.40 0.406 101.50 
0.60 0.608 101.33 
0.80 0.805 100.63 
1.00 1.004 100.40 
1.20 1.189 99.08 
– 
Mean (X) 
99.42 100.68 
± SD 2.58 1.20 
No of 
experiments  
 
7 
 
4 
Variance 6.656 1.44 
F
F-test 
4.62         (14,73)٭  
Students t-test 0.906       (2.26)٭  
N.B. Figures between parentheses are the tabulated F and t values respectively at  
P = 0.05 
[35]
.
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Table (3):Accuracy and Precision data of the proposed method for the determination of Tams.HCl in pure and 
dosage forms ( Tamsulin capsule). 
 
Parameter  
 
Intra-day precision 
(Repeatability) 
 
Inter-day precision 
(intermediate precision) 
Concentration 
μg mL
-1
 
 
 
0.40 
 
0.60 
 
0.80 
 
0.40 
 
0.60 
 
0.80 
 
 
%Recovery 
Of pure Tams 
 
101.50 
 
101.33 
 
100.63 
 
102.75 
 
99.17 
 
100.75 
 
100.00 
 
102.08 
 
100.85 
 
101.50 
 
100.20 
 
101.30 
 
101.00 
 
99.70 
 
98.25 
 
99.25 
 
97.80 
 
101.13 
          – 
Mean (X) 
 
100.83 
 
101.04 
 
99.91 
 
 
101.17 
 
99.06 
 
101.06 
 
± SD 
 
0.76 
 
1.20 
 
1.44 
 
1.77 
 
1.20 
 
0.28 
 
%RSD 
 
0.75 
 
1.19 
 
1.44 
 
1.75 
 
1.21 
 
0.28 
 
%Er 
 
0.83 
 
1.04 
 
0.09 
 
1.17 
 
0.94 
 
1.06 
 
%Recovery 
Tamsulin 
capsule  
 
 
101.38 
 
99.5 
 
99.88 
 
102.50 
 
100.00 
 
102.00 
 
99.01 
 
102.83 
 
100.63 
 
102.00 
 
102.20 
 
102.50 
 
101.8 
 
102.17 
 
100.38 
 
99.80 
 
101.8 
 
99.00 
           _ 
Mean (X) 
 
 
100.73 
 
101.50 
 
100.30 
 
101.43 
 
101.33 
 
101.17 
 
± SD 
 
1.50 
 
1.76 
 
0.38 
 
1.44 
 
1.17 
 
1.89 
%RSD  
1.49 
 
1.73 
 
0.38 
 
1.42 
 
1.15 
 
1.87 
%Er 
 
 
0.73 
 
1.50 
 
0.30 
 
1.43 
 
1.33 
 
1.17 
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Table (4): Application of the proposed method for the analysis of Tams.HCl in dosage form (Tamsulin capsule): 
Parameter proposed method Official method  
USP 
[3]
  
Concentration 
taken 
(μg mL
-1
) 
Concentration 
found 
(μg  mL
-1
) 
 
% Recovery 
         _ 
Mean (X) 
 
% Recovery  
 
 
0.40 
0.405 101.38  
100.73 
 
99.60 0.396 99.01 
0.407 101.80 
 
0.60 
0.597 99.50  
101.50 
 
101.4 
 
0.617 102.83 
0.613 102.17 
 
 
0.80 
 
0.799 99.88  
100.30 
 
101.9 0.805 100.63 
0.803 100.38 
 
1.00 
0.988 98.80  
100.13 
 
100.7 1.005 100.50 
1.011 101.10 
         _ 
Mean (X) 100.67 
 
100.90 
Nominal content 
of tamsulin 
capsule (mg) 0.403 
 
0.404 
 
± SD 0.611 
 
0.997 
 
%RSD 
 
0.807 
 
0.988 
 
% ER 
 
0.67 
 
0. 90 
No of 
experiments  
 
4 
 
4 
 
Variance 
 
0.37 
 
0.994 
 
F - test 
 
2.69      (15.44)٭  
 
Student
’
s t-test 
 
0.402     (2.45)٭  
 
N.B. Figures between parentheses are the tabulated F and t values respectively at  
P = 0.05 
[35]
. 
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Table (5): Application of the proposed method for the analysis of Tams.HCl in dosage form (Tamic capsule): 
Parameter proposed method Official method  
     USP 
[3]
 
Concentration 
taken 
(μg mL
-1
) 
Concentration 
found 
(μg  mL
-1
) 
 
% Recovery 
         _ 
Mean (X) 
 
% Recovery  
 
 
0.20 
0.201 100.50  
100 
 
99.65 
 
 
0.198 98.00 
0..203 101.50 
 
0.40 
0.409 102.25  
101.33 
 
98.70 0.405 101.25 
 0.402 100.50 
 
 
0.60 
 
0.611 101.83  
101.50 
 
98.10 0.603 100.50 
0..613 102.17 
 
0.8 
0.790 98.75  
98.79 
 
98.90 0.797 99.63 
0.784 98.00 
         _ 
Mean (X) 
 
100.41 
 
98.84 
Nominal content 
of tamic capsule 
(mg) 
 
0.402 
 
0..395 
 
± SD 
 
1.27 
 
0.64 
 
%RSD 
 
1.26 
 
0.65 
 
% ER 
 
0.41 
 
1.16 
No of 
experiments  
 
4 
 
4 
 
Variance 
 
1.61 
 
0.41 
 
F - test 
 
3.93       (15.44)٭  
 
Student
’
s t-test 
 
2.21      (2.45)٭  
 
N.B. Figures between parentheses are the tabulated F and t values respectively at  
P = 0.05 
[35]
.
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Table (6): Application of the proposed method for the analysis of Tams.HCl in spiked human plasma: 
Concentration 
added 
(μg ml
-1
) 
Concentration 
found 
(μg  ml
-1
) 
 
% Recovery 
 
 
0.4 
0.418 104.50 
0.430 107.50 
0.366 91.50 
0.375 93.75 
0.387 96.75 
 
 
0.8 
0.777 97.13 
0.815 101.90 
0.806 100.75 
0.824 103.00 
0.775 96.90 
 
 
0.8 
0.844 105.4 
0.828 103.50 
0.813 101.63 
0.724 90.50 
0.784 98.00 
         _ 
Mean (X) 
 
99.51 
± SD 5.1 
%RSD 5.13 
% ER 0.49 
 
Table (7): Determination of the molar absorbtivity of Tams.HCl in aqueous and micellar media: 
Concentration 
taken 
(μg ml
-1
)  
Absorbance 
In aqueous 
medium at 280 
nm 
 
ε water 
Absorbance 
In micellar 
medium at 280 
nm 
 
ε micellar  
 
ε micellar 
____________ 
ε water 
12.5 0.120 4270 0.124 4412.8 1.03 
25 0.240 4270 0.248 4412.8 1.03 
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Table (8): Determination of the fluorescence quantum yield of Tams.HCl in aqueous and micellar media: 
Concentration 
 
Taken of (Q.S.)  
(μg ml
-1
) 
 
Absorbance 
at 280 nm 
Integral 
fluorescence 
of (Q.S.)  
Concentration 
Taken of 
studied drug 
(μg ml
-1
) 
Integral 
fluorescence 
of studied drug 
In aqueous 
medium 
Integral 
fluorescence 
of studied drug 
In micellar 
medium 
5.0 0.01 14491 12.5 9072 16098 
10.0 0.02 29599 25 15871 26654 
 
N.B. Dilute solution of quinine sulfate dissolved in 0.05 M sulfuric acid with fluorescence quantum yield of 0.55 was used 
as reference reagent 
[36]
.   
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